TMCnet News

Research and Markets: Uveitis Pipeline Review, H1 2015
[June 11, 2015]

Research and Markets: Uveitis Pipeline Review, H1 2015


Research and Markets (http://www.researchandmarkets.com/research/hw3d2f/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective ounter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.



Companies Involved in Therapeutics Development

  • AbbVie Inc.
  • Aciont Inc.
  • Apitope International NV
  • BBB Therapeutics B.V.
  • Can-Fite BioPharma Ltd.
  • Clearside BioMedical, Inc.
  • Effimune SAS (News - Alert)
  • Eleven Biotherapeutics Inc.
  • Endocyte, Inc.
  • Enzo Biochem, Inc.
  • EyeGate Pharmaceuticals, Inc.
  • ForSight VISION4, Inc.
  • HanAll Biopharma Co., Ltd.
  • Icon Bioscience, Inc.
  • IMMD Inc.
  • Johnson & Johnson
  • Neuroptis Biotech
  • Novartis AG
  • Ocata Therapeutics, Inc.
  • OncoNOx ApS
  • Panoptes Pharma Ges.m.b.H.
  • Pfizer Inc.
  • pSivida Corp.
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • SynDevRx, Inc.
  • TxCell SA
  • Virogenomics, Inc.
  • XOMA Corporation

For more information visit http://www.researchandmarkets.com/research/hw3d2f/uveitis



[ Back To TMCnet.com's Homepage ]